Trial Profile
A phase 2 study of tandutinib in patients with newly diagnosed acute myelogenous leukemia who are considered ineligible for or who decline treatment with standard induction therapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Tandutinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 04 Jun 2008 Status changed from in progress to withdrawn prior to recruitment.
- 08 Aug 2006 New trial record.